Brief: Mesoblast Says US FDA Supports Accelerated Approval Pathway For Rexlemestrocel-L
10/03/2024 22:59
March 11 (Reuters) - Mesoblast Ltd MSB.AX :
* US FDA SUPPORTS ACCELERATED APPROVAL PATHWAY FOR
REXLEMESTROCEL-L
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil